Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay

Pavalan Selvam,Meng-Chang Hsiao,Gregory Omerza,Daniel Bergeron,Shannon Rowe,Jasmina Uvalic,Melissa Soucy,Michael Peracchio,Shelbi Burns,Bridgette Meyers,Matthew Prego,Qian Nie,Guruprasad Ananda,Harshpreet Chandok,Kevin Kelly,Andrew Hesse,Honey V. Reddi

Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay

2019

Pavalan Selvam
Meng-Chang Hsiao
Gregory Omerza
Daniel Bergeron
Shannon Rowe
Jasmina Uvalic
Melissa Soucy
Michael Peracchio
Shelbi Burns
Bridgette Meyers
Matthew Prego
Qian Nie
Guruprasad Ananda
Harshpreet Chandok
Kevin Kelly
Andrew Hesse
Honey V. Reddi

Objective The study aimed to retrospectively evaluate the positive yield rate of a custom 212-gene next-generation sequencing (NGS) panel, the JAX ActionSeq™ assay, used in molecular profiling of solid tumors for precision medicine.

Keywords:

Gene
Genetics
Precision medicine
Mutation
DNA sequencing
yield rate
Medicine
KRAS
Human genetics
Cancer
Molecular medicine
Oncology
ARID1A
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations